Itraconazole
- Generic Name
- Itraconazole
- Brand Names
- Sporanox, Tolsura
- Drug Type
- Small Molecule
- Chemical Formula
- C35H38Cl2N8O4
- CAS Number
- 84625-61-6
- Unique Ingredient Identifier
- 304NUG5GF4
- Background
One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis.
- Indication
For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.
- Associated Conditions
- Aspergillosis, Blastomycosis, Chromoblastomycosis, Coccidioidal meningitis, Esophageal Candidiasis, Fungal Infections, Fungal skin infection, Histoplasmosis, Onychomycosis, Oropharyngeal Candidiasis, Paracoccidioidomycosis, Penicillium marneffei infection, Pulmonary coccidioides, Sporotrichosis, Vulvovaginal Candidiasis, Disseminated Other specified protozoal diseases
- Associated Therapies
- -
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2017-03-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 148
- Registration Number
- NCT02341638
- Locations
- 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇺🇸Ppd Development, Lp, Austin, Texas, United States
Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI
- First Posted Date
- 2014-12-31
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT02328443
A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 94
- Registration Number
- NCT02323334
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-12-18
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 22
- Registration Number
- NCT02319148
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study of LY2623091 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2014-11-24
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 48
- Registration Number
- NCT02300259
- Locations
- 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States
Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps
- First Posted Date
- 2014-11-06
- Last Posted Date
- 2020-10-28
- Target Recruit Count
- 58
- Registration Number
- NCT02285283
- Locations
- 🇺🇸
University of Texas Medical School at Houston, Houston, Texas, United States
A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers
- First Posted Date
- 2014-10-23
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- Alkermes, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02272764
- Locations
- 🇺🇸
Alkermes Investigational Site, Overland Park, Kansas, United States
Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02264041
A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02259010
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2020-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 51
- Registration Number
- NCT02253420
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.